-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Public Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSBlog
Identifying Drug Protection in Canada
IQVIA Patent Intelligence
Jul 08, 2021
The pharmaceutical industry is one of the most regulated sectors of the healthcare system that facilitates the discovery, development, production, and commercialization of medicinal drugs. In order to ensure the health and safety of people, every country imposes an imperative regulatory system on the ever-growing pharmaceutical industry. There are dedicated federal departments or agencies to assure the safety, quality, and efficacy of drugs available in the market, such as the Food and Drug Administration in the United States, the European Medicines Agency in the European Union, and Health Canada in Canada.
For an innovator drug to be marketed in Canada, information gathered from preclinical studies and clinical trials must be submitted to Health Canada in a New Drug Submission (NDS). This NDS is then thoroughly reviewed and evaluated on the parameters of safety, efficacy, and quality of the drug(1,2). If the review concludes that the benefits of the drug outweigh the risks and the risks can be mitigated, a Notice of Compliance (NOC) and Drug Identification Number (DIN) are issued to the innovator. The NOC and DIN indicate that the drug is officially approved and can be marketed in Canada(3) (Figure 1). For the approval of generic drugs, companies can file an Abbreviated New Drug Submission (ANDS) by referring to and proving the “bioequivalence” to a Canadian Reference Product, the first version of the drug sold by an innovator manufacturer(4).
Regulatory Data Protection in Canada
While applying for regulatory approval, the applicant must submit the complete clinical and non-clinical data as part of the NDS. Health Canada rewards the innovator drug manufacturer with regulatory data protection and market exclusivity period for the long and complex drug development process. Under Food and Drug Regulations, data protection provisions provide an innovator drug six-years of New Chemical Entity (NCE) exclusivity and an additional two-years of market exclusivity (ME). A “no-file” limit imposed by Canada’s data protection regime prevents a generic drug manufacturer from filing an ANDS in the first six years when the NCE exclusivity is still active. The innovator drug can also qualify for additional six-months of pediatric extension (PED) if the manufacturer provides clinical trial data on the use of the drug in relevant pediatric populations(5).
In addition to the regulatory data protection in Canada, the innovator could also benefit from 20 years of patent protection which could be extended by two years of Certificates of Supplementary Protection (CSP). The CSP aims to compensate for the time spent in the development and approval phases, and it further impedes the generic competitors to enter the market. This form of protection can only be availed for a drug product that is market authorized with a NOC by Health Canada(6).
Using Ark Patent Intelligence to Identify Exclusivities
Using the Data Exclusivity module of Ark Patent Intelligence, it is possible to find various non-patent exclusivities such as NCEs, MEs and PEDs approved in Canada, along with their expiry dates.
There are 29 drugs that have their MEs expiring in 2026, which is the highest amongst the next five years, possibly indicating that in 2026 there are good opportunities for generics to enter the market (Figure 2). Although non-patent exclusivities are a constraint for the generics to enter the market, the generic manufacturer should also consider the patent protection and ongoing litigation to predict how soon they can enter the pharmaceutical market without any risk of infringement.
Information related to various drug approvals in Canada can also be found using a combination of the Market Authorizations and Data Exclusivity modules of Ark Patent Intelligence.
Conclusion
Health Canada ensures research and development momentum by implementing data protection laws in Canada. Innovator drug manufacturers can take benefit from data protection and exclusivities and can recoup their invested resources in the drug development process. The first six years of NCE protection prevent generic manufacturers from comparing to innovator drug and thus block the establishment of bioequivalence. Pediatric extensions and CSP can further extend the protection period of an innovator drug and thus qualifies as critical factors to be considered by a generic manufacturer who is looking to launch their product in the Canadian market.
References
1) https://www.canada.ca/en/health-canada/services/clinical-trials.html
Ark Patent Intelligence is produced by IQVIA, a global provider of intelligence for the pharmaceutical sector, and provides solutions to pharmaceutical firms in every continent. To find out more, please visit Ark Patent Intelligence